Varespladib methyl (A-002) (Synonyms: A-002; LY333013) |
Catalog No.GC31825 |
Varespladib methyl (A-002) (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (PLA2).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 172733-08-3
Sample solution is provided at 25 µL, 10mM.
Varespladib methyl is a selective inhibitor of group II secretory phospholipase A2 (PLA2).
Varespladib methyl (LY333013) is an orally-administered methyl ester pro-drug that is metabolized to LY315920[1]. Varespladib and its orally bioavailable prodrug, Varespladib methyl (methyl-Varespladib) shows high-level secretory PLA2 (sPLA2) inhibition at nanomolar and picomolar concentrations against 28 medically important snake venoms from six continents[2].
[1]. Bradley JD, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol. 2005 Mar;32(3):417-23. [2]. Lewin M, et al. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins (Basel). 2016 Aug 25;8(9). pii: E248.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *